This is a routine insider monetization via option exercise, not a distress signal. The sale is moderate in size relative to the insider's total position and the company's $6.2B market cap. Monitor for actual Form 4 filings to confirm execution. No immediate trading action warranted.
MIRM drugs
MIRM drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 2 $92.17entry
- T+1 · 6mo ago −0.36%α +0.36% · $91.84
- T+5 · 5mo ago +3.59%α +6.56% · $95.48
- T+20 · 5mo ago +30.69%α +32.26% · $120.46
- T+60 · 3mo ago +6.88%α +5.76% · $98.51
Price Chart
How similar events traded
Executive Summary
Christopher Peetz, an officer and director of Mirum Pharmaceuticals, filed a Form 144 notice of intent to sell 30,000 shares of common stock, with an approximate market value of $2.88 million based on the filing date. The shares were acquired via stock option exercise on the same day, suggesting a cashless exercise-and-sell transaction. While the sale is modest relative to Peetz's remaining holdings (40,985 shares worth ~$3.77 million as of March 2026), the filing signals insider intent to monetize equity ahead of any potential catalyst.
Key Facts
- Insider Christopher Peetz (officer and director) filed Form 144 to sell 30,000 shares
- Sale value approximately $2.88 million based on filing date
- Shares were acquired via stock option exercise on June 1, 2026
- Peetz retains 40,985 shares (worth ~$3.77 million as of March 2026)
- Sale represents ~42% of total holdings (30,000 / 70,985 shares)
- No lock-up expiration or earnings catalyst mentioned in filing
Financial Impact
Proposed sale of 30,000 shares valued at ~$2.88 million, representing ~42% of insider's disclosed holdings
Risk Factors
- Insider may be reducing exposure ahead of a catalyst or earnings event not disclosed in this filing
- Form 144 is intent to sell; actual sale may not occur or may differ in size/timing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-005448 |
| Document: 0001950047-26-005448-index.html | 0001950047-26-005448 |
| Document: 0001950047-26-005448.txt | 0001950047-26-005448 |
Track record
27 reports on MIRM
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +28.29% at T+20 after the Jun 11, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $92.28 Now $91.58 −0.76% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 3/10 Entry $93.54 Now $91.58 −2.10% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $93.33 Now $91.58 −1.88% settles Feb 10
- Nov 10, 20266d ago 8-K Bullish 6/10 Entry $94.42 Now $91.58 −3.01% settles Feb 8
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $96.97 Now $91.58 −5.56% settles Feb 2
- Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $85.81 Now $91.58 +6.72% settles Jan 26
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $85.56 Now $91.58 +7.04% settles Jan 25
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $79.62 Now $91.58 +15.02% settles Jan 8
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers